Biovica International B
Develops blood tests to monitor the efficacy of solid tumor cancer therapies.
BIOVIC | ST
Overview
Corporate Details
- ISIN(s):
- SE0008613681 (+3 more)
- LEI:
- 549300VADE1VRR555N78
- Country:
- Sweden
- Address:
- Dag Hammarskjölds väg 54B, 752 37 Uppsala
- Website:
- https://biovica.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Biovica International is a biotechnology company, founded in 2009, that develops and commercializes blood-based biomarker assays to improve the monitoring of cancer therapies and predict patient outcomes. The company's primary product is the DiviTum® TKa test, a novel blood test that measures cell proliferation to monitor disease progression from solid tumors. With an initial focus on metastatic breast cancer, DiviTum® TKa is designed to provide oncologists with early and valuable insights into treatment efficacy, supporting more confident and personalized therapeutic decisions for patients.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Biovica International B and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| No filings match the current criteria. | ||||
Automate Your Workflow. Get a real-time feed of all Biovica International B filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Biovica International B via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
